Glide Control for Upper Extremity Amputation
Trial Summary
What is the purpose of this trial?
The investigators will test the following hypothesis: Use of Glide results in improved functional performance, satisfaction, and usage metrics as compared to use of a standard Direct Control (DC) prosthesis. This study will compare the use of Glide \[Experimental\] prosthesis with a DC \[Standard\] prosthesis in a clinical setting and in unsupervised daily activity. We will follow a multiple baseline design, specifically an AB design. Each of the subjects will use the Experimental and Standard systems over a total of 24-weeks. The A phase is the baseline phase where the DC prosthesis will be used, and the B phase will be the treatment phase where the Glide prosthesis will be used. Participants will undergo an A phase of either 10-weeks, 12-weeks, or 14-weeks duration, with the remaining 14-, 12-, or 10-weeks of the study being dedicated to the B phase.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It would be best to discuss this with the study team.
What data supports the effectiveness of the treatment Glide Control Strategy, Glide Myoelectric Control Algorithm, Glide Control Strategy for upper extremity amputation?
Research shows that myoelectric control, which is part of the Glide Control Strategy, has been effectively used for over 30 years to help people control prosthetic limbs. This type of control allows for more natural and easier operation of prosthetic devices, making it a reliable option for improving function in individuals with upper limb amputations.12345
Is the Glide Control for Upper Extremity Amputation generally safe for humans?
The research on myoelectric control systems, which includes various control strategies for prosthetic limbs, has been ongoing for decades and is considered reliable and durable in most situations. While specific safety data for Glide Control is not mentioned, myoelectric control systems have been used extensively and are generally safe for human use.34678
How does the Glide Control Strategy treatment differ from other treatments for upper extremity amputation?
The Glide Control Strategy is unique because it uses a myoelectric control algorithm that allows for more natural and intuitive control of prosthetic limbs by creating additional control signals through nerve transfers to spare muscles. This enables simultaneous control of multiple joints, offering a more seamless and functional experience compared to traditional prosthetic control methods.123910
Eligibility Criteria
This trial is for individuals with upper extremity amputation. Participants will use two types of prosthetic arms: a standard Direct Control (DC) prosthesis and an experimental Glide prosthesis, over a period of 24 weeks to compare functionality, satisfaction, and usage.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Baseline (A Phase)
Participants use the Direct Control (DC) prosthesis for baseline measurements and daily activities
Crossover
Participants transition from DC to Glide control strategy and receive occupational therapy training
Treatment (B Phase)
Participants use the Glide prosthesis for treatment measurements and daily activities
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Glide Control Strategy
Glide Control Strategy is already approved in United States, European Union for the following indications:
- Upper limb amputation
- Partial hand limb loss
- Upper limb amputation
- Partial hand limb loss
Find a Clinic Near You
Who Is Running the Clinical Trial?
Infinite Biomedical Technologies
Lead Sponsor
Advanced Arm Dynamics
Collaborator
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborator